Usefulness of Controlled Attenuation Parameter (CAP) for the Assessment of Liver Steatosis

Overview

About this study

The primary aim of this study is to determine the accuracy of CAP from Fibroscan in the quantification of liver steatosis in donors using liver biopsies as the gold standard.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Liver Recipient

Men and women
Age 18-years old to 80-years old inclusive

Liver Donor

Valid TE with Fibroscan 530, defined as:
- At least 10 valid measurements
- IQR/Median stiffness value <30% (only in cases with >7.1 kPa)

Exclusion Criteria:

Liver Recipient

Patient did not undergo liver transplantation

Liver Donor

Donation after circulatory death (DCD)
No liver biopsy obtained during organ procurement process

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Julie Heimbach, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Julie Heimbach, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials